Understanding how VPS72 affects immune cells in tumors
Official title: VPS72 controls Treg cell stability and adaptation to tumor microenvironment
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-10931580 · Data updated 2026-11-12
This study is looking at a protein called VPS72 to see how it affects certain immune cells that help control the body's response to tumors, and by understanding this better, we hope to find new ways to improve cancer treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $602,346 |
| NIH project number | 5R01CA284740-02 |
| Project ID | NIH-10931580 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that exhibit immune evasion, particularly those where Treg activity is suspected to play a role.
✕Less likely to help
Patients with non-cancerous conditions or those whose tumors do not involve Treg interactions may not benefit from this research.
What this research studies
This research investigates the role of VPS72, a protein that influences the behavior of regulatory T cells (Tregs) within the tumor microenvironment. By studying mouse models, the researchers aim to uncover how VPS72 contributes to Treg stability and function, which are crucial for the immune system's ability to respond to tumors. The approach involves advanced techniques to analyze gene expression and chromatin remodeling, providing insights into the mechanisms that allow tumors to evade immune detection. Patients may benefit from a deeper understanding of Treg behavior in cancer, potentially leading to improved therapies.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for enhancing the immune response against tumors, improving cancer treatment outcomes.
How similar studies have gone: Previous research has shown promising results in understanding Treg dynamics in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Mi, Qing-Sheng — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Mi, Qing-Sheng
Related research
Other NIH-funded projects on the same topics.
-
Keloid recurrence study using multi-omics in diverse patients
A research effort will look at why keloids come back after surgery, especially in African American patients, using comprehensive molecular data from patient samples.
-
A national program to build a precise, personalized health data platform for all of us participants
This grant supports expanding and improving a national health data platform to help tailor care to each person using their genetic, health, and lifestyle information.
-
Computational modeling of female hormone balance and drug responses
A new computational model uses patient-like data to predict how metabolic drugs will work in women across their hormonal cycles and different reproductive stages.
-
Anti-CD38 immunotherapy for severe hidradenitis suppurativa
A new treatment using anti-CD38 therapy is being tested for people with severe hidradenitis suppurativa who have not responded to prior therapies.
-
Vitamin D, gut bacteria and dementia risk in older adults with HIV
This work will look at whether low vitamin D and changes in gut bacteria are linked to higher dementia risk in older adults living with chronic HIV and similar community members.
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.